Good MorningEquity markets will open near an all-time high following the Juneteenth holiday and will likely continue higher over the summer. The FOMC and inflation remain reasons to worry but have become a pile of bricks used to build a Wall of Worry that keeps increasing. The market is moving higher on earnings growth and will likely rally until the outlook for earnings changes, and there are only two possibilities to look forward to.
The first is a soft landing for the economy, an interest rate cut, and S&P 500 earnings stability, if not growth. The second scenario includes a hard landing, recession, and earnings contraction. In the first scenario the S&P 500 can continue to rally indefinitely, in the second a significant correction would follow. The question for investors is if the economy can sustain growth until the FOMC cuts rates or if it will reach its peak and begin to recede before they do. As it is, the first cut isn't expected until November, and it may not come then. Featured: AI “wealth window” will close June 25 (Paradigm Press) 
|
Markets | | |
One of the most significant economic indicators has just turned into expansion mode after leaving investors concerned about the Federal Reserve (the Fed) not following through with its plans to cut interest rates by the end of 2024. The M2 money supply is now back into expansion to change its prev... Read the Full Story |
|
From Our PartnersThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone.
Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture. | | | | Get the name and ticker symbol for free - just click here. |
|
Markets | | |
Outlook Therapeutics (NASDAQ: OTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target.
It's essential to remember that low-float biopharmaceutical companies often experience volatility due to frequent breaking news and technical fac... Read the Full Story |
|
Markets | | |
Zebra Technologies (NASDAQ: ZBRA) stock hit bottom in 2023, but it took until this year for the reversal to be completed. Now, the stock is up 50% from the recent low and heading higher under the influence of analysts. Analysts' sentiments also bottomed during the last twelve months, and a rever... Read the Full Story |
|
|
Markets | | | Japan's exports surged 13.5% in May, faster than expected growth helped by a weak yen and strong demand in the U.S. and Asia. Finance Ministry data reported Wednesday showed that the trade deficit totaled 1.22 trillion yen ($7.7 billion), down nearly 12% from 1.38 trillion yen a year earlier. Import... Read the Full Story |
|
Markets | | | World stocks were mixed on Wednesday after U.S. benchmarks ticked to more records following the latest signs that the U.S. economy may be slowing without falling into recession.The future for the Dow Jones Industrial Average was down 0.1% while that for the S&P 500 rose 0.1%. U.S. markets are cl... Read the Full Story |
|
|
Markets | | |
Oil prices (NYSEARCA: USO) are near the low end of a multi-year trading range, aiding the broad market rally in stocks. Oil prices are a fundamental driver of inflation that compounds within the economy, and the inflation outlook is driving the market. Lower oil prices undercut inflation.
... Read the Full Story |
|
Markets | | | Toyota shareholders have voted in support of all of the company's proposals at their annual meeting, including keeping Akio Toyoda, the grandson of the Japanese automaker’s founder, as chairman of the board Read the Full Story |
|
Markets | | |
Global food and beverage company Campbell Soup Co. (NYSE: CPB) reported solid earnings accompanied by raised guidance, but the market continued to sell off shares. However, clues were sprinkled throughout its earnings presentation that indicate a return of growth acceleration is coming in the se... Read the Full Story |
|
Markets | | | The Bank of England on Thursday kept its main interest rate at a 16-year high of 5.25% even though inflation has fallen to its target of 2%, with several policymakers warning that a premature cut could stoke another bout of price rises.For the second meeting in a row, seven of the nine members of th... Read the Full Story |
|
Markets | | | Apple is discontinuing its buy now, pay later service known as Apple Pay Later barely a year after its initial launch in the U.S., and will rely on companies who already dominate the industry like Affirm and Klarna Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. | | View Today's Stock Pick |
|
